By Alice Goodman December 10, Advertisement. Recent studies have more clearly defined the role of pertuzumab Perjeta and neratinib Nerlynx. A question currently on the table is the optimal duration of trastuzumab. A recent study Persephone demonstrated that 6 months of trastuzumab is noninferior to 1 year. This is a more attractive option because of reduced potential for side effects, lower cost, and patient convenience, but experts agree that shorter treatment duration has not been definitively established.
Management of HER2-Positive Breast Cancer: Business as Usual?
HER2-positive breast cancer: Causes, prevalence, and diagnosis
The past 30 years have seen many advances in the treatment of breast cancer. This protein is an important part of the pathway for cell growth and survival. A targeted therapy is a drug designed to attack a particular molecular agent or pathway involved in the development of cancer. Unlike chemotherapy drugs, targeted therapies kill cancer cells with little harm to healthy cells. A targeted therapy will only work on cancers that have the specific marker it was designed to attack. Different anti-HER2 drugs work in different ways.
For full functionality, it is necessary to enable JavaScript. Here are instructions how to enable JavaScript in your web browser. Healthline Media, Inc. Any data you provide will be primarily stored and processed in the United States, pursuant to the laws of the United States, which may provide lesser privacy protections than European Economic Area countries.
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 HER2 , which promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.